In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Co-morbid conditions and their relationship with mortality in elderly heart failure patients

Session Poster Session 1

Speaker Vera Larina

Event : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure – Epidemiology, Prognosis, Outcome
  • Session type : Poster Session

Authors : VN Larina (Moscow,RU), DG Karpenko (Moscow,RU), VG Larin (Moscow,RU)

Authors:
VN Larina1 , DG Karpenko1 , VG Larin1 , 1Pirogov Russian National Research Medical University , Oupatient Medicine - Moscow - Russian Federation ,

Citation:

In recent years, there has been growing evidence that multimorbidity is associated with the poor prognosis of chronic heart failure (CHF), but less is known about how these conditions impact outcomes in elderly patients.

Aim. To assess the ?o-morbid conditions and their relationship with mortality in elderly CHF outpatients. Methods. Eighty outpatients suffering from CHF (44% F/56% M, age 60-89 years) due to coronary heart disease (CHD) or arterial hypertension entered the study. Forty subjects with cardiovascular diseases but without CHF (45% F/55% M, age 60-88 years) were selected as sex- and age-matched controls. All patients provided written informed consent and had clinical, laboratorial evaluation, Echo CG measurements. Frailty was identified according to the score 3 or greater due to questionnaire FRAIL. Validated Charlson comorbidity index (CCI) was calculated. Bone mineral density (BMD) in the femoral neck (FN) were examined using dual-energy X-ray absorptiometry. Statistical analysis was made using software packages SPSS 21.0, Stata 15. Results. Co-morbidity (2 or more chronic conditions) was present in all patients  with CHF and in 92,5% of control group. The most common comorbid conditions in CHF were chronic kidney disease (CKD, 66%), osteoporosis (58,6%), falls (48,5%), frailty (42,5%), obesity (35%); in control group - obesity (42%) or CKD (40%). The prevelance of osteoporosis (26,1%, p=0,005), falls (25%, p=0,039), frailty (5%, p<0,001) was less in control group compared to patients with CHF. The most common comorbid conditions ?ombinations in CHF were osteoporosis and CKD (28%), obesity and CKD (23%), in control group – obesity and CKD (28%), obesity and diabetes (18%). Frailty associated with age of 75 years or higher (p=0,001, OR 6,0, 95% CI 2,1-17,5), CKD (p<0,001, OR 18,9, 95% CI 5,2-20,2), osteoporosis (p=0,019, OR 4,5, 95% CI 1,3-15,8) and past myocardial infarction (p=0,001, OR 6,8, 95% CI 2,2-20,8). During the mediana of follow-up 24,1±13,0 months the mortality rate was the same in the CHF patients with =3 diseases or <3 diseases (?=0,164). Patients with CHD (p=0,016), history of myocardial infarction (MI, p=0,016), osteoporosis (p=0,018) appear to have aggravated mortality. The relationship of mortality with male gender  (?=0,001, ?R 7,9, 95% CI 2,3 - 27,2), CHD (?=0,039, ?R 8,3, 95% CI 1,1-62,4), history of MI (?=0,027, OR 3,5, 95% CI 1,2-10,5), low BMD in FN region (?=0,016, ?R 4,3, 95% CI 1,3-17,2), CCI (?=0,012, ?R 1,2, 95% CI 1,04-1,4) was confirmed. Conclusion. Co-morbidities are prevalent in elderly patients with CHF. The presence of CHD, osteoporosis and complex of co-morbidities defined by CCI was indepedently related to increased mortality.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are